Pterostilbene Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Pterostilbene Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Pterostilbene can convert its Small molecule drug profile and HDAC1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Pterostilbene (query alias: Pterostilbene) |
|---|---|
| Modality / target | Small molecule drug; HDAC1; HDAC1 inhibitors, Epigenetic drug |
| Highest global status | Phase 2 |
| Originator | Not disclosed |
| Active developers | University of British Columbia, Beijing Hospital of the Ministry of Health, Institute for Myeloma & Bone Cancer Research |
The MCP disease footprint includes Endometrioid intraepithelial neoplasia, Cystitis, Interstitial, Neurodegenerative Diseases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07579429 | Phase 2 | Recruiting | 10 | Preliminary Efficacy: Cytopenia Improvement |
| JPRN-jRCTs031220638 | Not Applicable | Recruiting | 520 | 受精後5日目の胚盤胞到達率（胚盤胞数／正常受精卵数） |
| JPRN-jRCTs031210153 | Not Applicable | Complete | 460 | 受精後5日目の胚盤胞到達率 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy
Phase 2; n=44; evaluation: not stated. Reported fields: Tumor Ki-67 Proliferation Index(Mean): P-Value = 0.9; Tumor Ki-67 Proliferation Index(Mean) = -26.7 percent change (Standard Deviation, 34.1); Tumor Ki-67 Proliferation Index(Mean) = -25.7 percent change (Standard Deviation, 36.3)
The effect of megestrol acetate ± pterostilbene in endometrial cancer: A prospective, randomized, window-of-opportunity clinical trial.
Phase 2; n=44; evaluation: Positive. Reported fields: Ki-67 index = -27.5 % ; Ki-67 index = -41.1 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Pterostilbene addresses Endometrioid intraepithelial neoplasia, Cystitis, Interstitial, Neurodegenerative Diseases. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 11 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HDAC1 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-09-27 | Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer | Approved | Financial terms not disclosed |
| 2022-10-01 | 安邦與台北醫學大學簽署了ABT-301授權合約 | Phase 1 | Financial terms not disclosed |
| 2019-09-02 | Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Pterostilbene preparation point as well as preparation method and application thereof”. The milestone feed surfaced a patent-application signal described as “Yarrowia lipolytica engineering bacterium for synthesizing pterostilbene as well as construction method and application of Yarrowia lipolytica engineering bacterium”. The milestone feed surfaced a patent-application signal described as “Aqueous core nanocapsule of pterostilbene and resveratrol for treatment of prostate cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
